BRYCE RICHARD PAUL 4
4 · PUMA BIOTECHNOLOGY, INC. · Filed Mar 4, 2021
Insider Transaction Report
Form 4
BRYCE RICHARD PAUL
SR VP, CLINICAL RESEARCH & DEV
Transactions
- Sale
COMMON STOCK
2021-03-02$10.15/sh−422$4,283→ 122,088 total
Footnotes (1)
- [F1]The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units.